Geode Capital Management
TARA icon

Geode Capital Management’s Protara Therapeutics TARA Stock Holding History

Geode Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.13M Buy
1,177,200
+360,004
+44% +$2.13M ﹤0.01% 2640
2025
Q4 		$4.36M Buy
817,196
+58,477
+8% +$325K ﹤0.01% 2850
2025
Q3 		$3.3M Buy
758,719
+14,200
+2% +$46K ﹤0.01% 2988
2025
Q2 		$2.26M Buy
744,519
+397,822
+115% +$1.37M ﹤0.01% 3102
2025
Q1 		$1.48M Buy
346,697
+167,104
+93% +$747K ﹤0.01% 3162
2024
Q4 		$948K Buy
179,593
+9,553
+6% +$30.9K ﹤0.01% 3404
2024
Q3 		$311K Buy
170,040
+29,514
+21% +$60.6K ﹤0.01% 3756
2024
Q2 		$292K Buy
140,526
+57,619
+69% +$168K ﹤0.01% 3782
2024
Q1 		$333K Buy
82,907
+4,389
+6% +$14.2K ﹤0.01% 3763
2023
Q4 		$147K Hold
78,518
– – ﹤0.01% 4050
2023
Q3 		$131K Sell
78,518
-4,902
-6% -$11.2K ﹤0.01% 4154
2023
Q2 		$199K Hold
83,420
– – ﹤0.01% 4041
2023
Q1 		$259K Hold
83,420
– – ﹤0.01% 3920
2022
Q4 		$223K Sell
83,420
-224
-0.3% -$707 ﹤0.01% 4041
2022
Q3 		$247K Hold
83,644
– – ﹤0.01% 4081
2022
Q2 		$245K Buy
83,644
+1,680
+2% +$6.14K ﹤0.01% 4143
2022
Q1 		$418K Buy
81,964
+2,947
+4% +$15.5K ﹤0.01% 4030
2021
Q4 		$533K Hold
79,017
– – ﹤0.01% 4011
2021
Q3 		$546K Sell
79,017
-3,968
-5% -$30.9K ﹤0.01% 3990
2021
Q2 		$808K Sell
82,985
-28,077
-25% -$318K ﹤0.01% 3712
2021
Q1 		$1.75M Buy
111,062
+6,182
+6% +$115K ﹤0.01% 3317
2020
Q4 		$2.54M Buy
104,880
+84,598
+417% +$1.82M ﹤0.01% 2949
2020
Q3 		$341K Buy
20,282
+2,838
+16% +$65.8K ﹤0.01% 3557
2020
Q2 		$511K Buy
+17,444
New +$540K ﹤0.01% 3369
2020
Q1 		– Sell
-3,892
Closed -$63K – 4173
2019
Q4 		$63K Hold
3,892
– – ﹤0.01% 4053
2019
Q3 		$40K Hold
3,892
– – ﹤0.01% 4086
2019
Q2 		$64K Buy
3,892
+3,083
+381% +$54.5K ﹤0.01% 4047
2019
Q1 		$16K Hold
809
– – ﹤0.01% 4106
2018
Q4 		$73K Hold
809
– – ﹤0.01% 3920
2018
Q3 		$63K Hold
809
– – ﹤0.01% 4003
2018
Q2 		$79K Hold
809
– – ﹤0.01% 3919
2018
Q1 		$80K Hold
809
– – ﹤0.01% 3882
2017
Q4 		$61K Sell
809
-56
-6% -$4.49K ﹤0.01% 3899
2017
Q3 		$69K Hold
865
– – ﹤0.01% 3884
2017
Q2 		$53K Sell
865
-86
-9% -$4.82K ﹤0.01% 3950
2017
Q1 		$66K Buy
951
+12
+1% +$897 ﹤0.01% 3902
2016
Q4 		$71K Buy
939
+7
+0.8% +$2.21K ﹤0.01% 3855
2016
Q3 		$347K Buy
932
+2
+0.2% +$704 ﹤0.01% 3395
2016
Q2 		$298K Sell
930
-205
-18% -$61.3K ﹤0.01% 3432
2016
Q1 		$351 Buy
1,135
+67
+6% +$21.6K ﹤0.01% 3407
2015
Q4 		$662K Buy
1,068
+26
+2% +$15.3K ﹤0.01% 3125
2015
Q3 		$579K Buy
1,042
+30
+3% +$18.6K ﹤0.01% 3162
2015
Q2 		$723K Buy
1,012
+440
+77% +$272K ﹤0.01% 3051
2015
Q1 		$266K Buy
572
+297
+108% +$130K ﹤0.01% 3470
2014
Q4 		$114K Buy
+275
New +$111K ﹤0.01% 3756

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Geode Capital Management's TARA Position: Q1 2026 in Review

Geode Capital Management increased its Protara Therapeutics (TARA) stake by 44% in Q1 2026, buying an estimated $2.13M and bringing the position to 1,177,200 shares worth $6.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2640.

Geode Capital Management first reported a position in TARA in Q4 2014 and has held it in 45 quarters since. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Geode Capital Management held 1,177,200 shares of Protara Therapeutics worth $6.13M as of Q1 2026.
  • Geode Capital Management bought 360,004 Protara Therapeutics shares in Q1 2026, an estimated $2.13M.
  • Protara Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2640 holding.
  • Geode Capital Management first reported a position in Protara Therapeutics in Q4 2014 and has held it in 45 quarters since.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.